Array Jumps as Colon Cancer Combo Helps Patients Live Longer
This article is for subscribers only.
Shares of Array BioPharma Inc. climbed as much as 17%, the most since February, after results in colon cancer suggest the drug-maker may have the first chemotherapy-free regimen targeting a genetic mutation for patients with advanced disease.
Array’s triple combination therapy from helped colon cancer patients live longer in an interim analysis of more than 600 patients whose BRAF-mutant colon cancer had returned showed those getting Braftovi, Mektovi and Eli Lilly & Co’s Erbitux together survived for 9.0 months while those getting just Erbitux with chemotherapy lived for 5.4 months. Patients getting Braftovi and Erbitux lived 8.4 months.